CRNX

SEC source: 0001209191-23-006872 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,689

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-23-005252 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,815

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.07 per share. The range of sales prices on the transaction date was $21.00 to $21.08 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0001209191-23-004021 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,151

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-23-001846 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,277

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-061986 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,403

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · balance_after: Includes 561 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022 by the Reporting Person.

SEC source: 0001209191-22-059779 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,968

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-23-005258 · doc5.xml · nonDerivative · entry 2

Wilson Marc · CIK 0001702265 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,546

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-23-005254 · doc5.xml · nonDerivative · entry 2

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,488

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-23-005253 · doc5.xml · nonDerivative · entry 1

Knight Jeff E. · CIK 0001881007 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,487

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-22-057585 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,094

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-055522 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,220

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-054104 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,346

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-053680 · doc4.xml · derivative · entry 7

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,270

Underlying: Common Stock · 11,100 shares

Expires 2028-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001209191-22-053680 · doc4.xml · nonDerivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-053313 · doc4.xml · derivative · entry 2

Pizzuti Dana · CIK 0001948238 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,000

Underlying: Common Stock · 230,000 shares

Expires 2032-10-09

F2 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001209191-22-053313 · doc4.xml · nonDerivative · entry 1

Pizzuti Dana · CIK 0001948238 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on March 30, 2023.

SEC source: 0001209191-22-052769 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,472

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-050529 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,598

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-049311 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,766

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-048734 · doc4.xml · nonDerivative · entry 2

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,808

F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-043524 · doc4.xml · nonDerivative · entry 2

Knight Jeff E. · CIK 0001881007 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,950

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.7004 per share. The range of actual sales prices on the transaction date was $20.69 to $20.7016 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

SEC source: 0001209191-22-042245 · doc4.xml · derivative · entry 3

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 5,700 shares

Expires 2027-11-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017.

SEC source: 0001209191-22-042245 · doc4.xml · nonDerivative · entry 2

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,536

F2 · kind: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017.

SEC source: 0001209191-22-042245 · doc4.xml · nonDerivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,236

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-038442 · doc4.xml · derivative · entry 1

WIERENGA WENDALL · CIK 0001235945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-038441 · doc4.xml · derivative · entry 1

Vivaldi Coelho Rogerio · CIK 0001610381 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,750

Underlying: Common Stock · 8,750 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-038440 · doc4.xml · derivative · entry 1

Okey Stephanie · CIK 0001742616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-038439 · doc4.xml · derivative · entry 1

Nichols Weston · CIK 0001746376 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-038438 · doc4.xml · derivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-038436 · doc4.xml · derivative · entry 1

Deardorf Caren · CIK 0001871152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,375

Underlying: Common Stock · 4,375 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-038435 · doc4.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-22-043524 · doc4.xml · nonDerivative · entry 1

Knight Jeff E. · CIK 0001881007 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,102

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).

SEC source: 0001209191-22-048734 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,934

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).

SEC source: 0001209191-23-005258 · doc5.xml · nonDerivative · entry 1

Wilson Marc · CIK 0001702265 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,064

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-23-005254 · doc5.xml · nonDerivative · entry 1

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,776

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),

SEC source: 0001209191-22-027145 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,598

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.096 per share. The range of sales prices on the transaction date was $20.06 to $21.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0001062993-22-010385 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,321,032

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-22-025190 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,845

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-024531 · doc4.xml · nonDerivative · entry 3

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 1

Disclosed balance after: 730,805

F1 · kind: The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F4 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.5277 per share. The range of actual sales prices on the transaction date was $27.02 to $27.845 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

SEC source: 0001209191-22-024531 · doc4.xml · nonDerivative · entry 2

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 1

Disclosed balance after: 799,981

F1 · kind: The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $26.5229 per share. The range of actual sales prices on the transaction date was $26.02 to $27.005 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

SEC source: 0001209191-22-024531 · doc4.xml · nonDerivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 1

Disclosed balance after: 844,774

F1 · kind: The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.4247 per share. The range of actual sales prices on the transaction date was $25.00 to $25.98 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

SEC source: 0001209191-22-023722 · doc4.xml · nonDerivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 1

Disclosed balance after: 869,448

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.3418 per share. The range of actual sales prices on the transaction date was $25.00 to $25.57 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

SEC source: 0001209191-22-023556 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,509

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $23.9735 per share. The range of sales prices on the transaction date was $23.9515 to $24.0027 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0001209191-22-022036 · doc4.xml · nonDerivative · entry 2

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,509

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-022036 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,673

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.0614 per share. The range of sales prices on the transaction date was $21.0201 to $21.0774 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0001209191-22-019595 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,837

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-018577 · doc4.xml · derivative · entry 1

Deardorf Caren · CIK 0001871152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to continued service as a director through each such vesting date.

SEC source: 0001209191-22-022682 · doc4a.xml · derivative · entry 1

Deardorf Caren · CIK 0001871152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-03-10

F1 · shares: On March 14, 2022, the reporting person filed a Form 4 which inadvertently reported that she was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.

F2 · derivative.exercise_date: The Option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the date of grant, subject to continued service as a director through each such vesting date.

F1 · derivative.underlying_shares: On March 14, 2022, the reporting person filed a Form 4 which inadvertently reported that she was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.

F1 · balance_after: On March 14, 2022, the reporting person filed a Form 4 which inadvertently reported that she was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.

SEC source: 0001209191-22-017938 · doc4.xml · derivative · entry 1

Hassard James · CIK 0001799357 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001209191-22-015130 · doc4.xml · nonDerivative · entry 2

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,960

F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.